Sector: MedicalEndo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP)
Ranking History
Scan Date: | 2/2/2010 |
Sector: | Medical |
Funamental : | 279 |
Technical : | 233 |
Performance : | 250 |
Overall: | 294 |
Number of Stocks: | 309 |
Scan Date: | 1/26/2010 |
Sector: | Medical |
Funamental : | 279 |
Technical : | 247 |
Performance : | 261 |
Overall: | 299 |
Number of Stocks: | 309 |
Scan Date: | 1/19/2010 |
Sector: | Medical |
Funamental : | 278 |
Technical : | 248 |
Performance : | 270 |
Overall: | 301 |
Number of Stocks: | 308 |
Headlines
- Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification
Jan 19, 2010 08:03 AM | ENDP
- Endo to Present at J.P. Morgan 28th Annual Healthcare Conference
Dec 30, 2009 09:00 AM | ENDP
- Endo Pharma downgraded by analyst
Dec 07, 2009 02:31 PM | ENDP, TRI
- Endo Pharmaceuticals Provides Regulatory Update on AVEED(TM) (Testosterone Undecanoate) Injection
Dec 03, 2009 08:43 AM | ENDP
- Biotech 2009 to Feature Global Industry Leaders and Cover the Latest Topics and Trends Relevant to the Bioscience Industry
Nov 12, 2009 10:50 AM | ENDP
- Endo Pharmaceuticals and LecTec Settle Patent Dispute
Nov 11, 2009 04:14 PM | ENDP
- Bioniche communique ses résultats pour le premier trimestre de 2010 et annonce l'atteinte d'une première étape dans le cadre d'une entente de licence
Nov 06, 2009 02:29 PM | ENDP
- RXi Pharmaceuticals Appoints Noah D. Beerman as CEO
Nov 06, 2009 07:15 AM | ENDP
- Bioniche Reports Fiscal 2010 First Quarter Results And Achievement of First Milestone Under Licensing Agreement
Nov 06, 2009 07:01 AM | ENDP
- Partnerships in Clinical Trials Expands Its Global Reach
Nov 02, 2009 10:56 AM | ENDP
- Analyst Choice Offers Latest Analysis of Financial, Healthcare and Technology Sectors
Jan 05, 2010 07:55 AM | ADCT, ENDP, PNC, RMBS, STI, TEVA
- Endo Pharmaceuticals Announces Resignation of Chief Operating Officer
Aug 12, 2009 08:31 AM | ENDP
- Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results
Jul 30, 2009 10:51 AM | ENDP, NVS
- Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results
Jul 30, 2009 07:53 AM | ENDP, NVS
- BenchmarkJournal.Com Free Analyst Review for QLGC, NEXM, GERN, ENDP, LOGI and ALXN
Jul 21, 2009 10:23 AM | ALXN, ENDP, GERN, LOGI, NEXM, QLGC
- Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)
Jul 10, 2009 08:01 AM | ENDP
- Bioniche Life Sciences Inc. and Endo Pharmaceuticals Inc. Sign Licensing Agreement for Urocidin(TM)
Jul 10, 2009 08:00 AM | ENDP
- Endo Pharmaceuticals to Announce Second Quarter 2009 Financial Results on July 30, 2009
Jul 01, 2009 04:52 PM | ENDP
- Men with Low Testosterone See Multiple Doctors Before Being Diagnosed; Many Dissatisfied with Current Treatment Options
Jun 10, 2009 08:31 AM | ENDP
- Penwest and Endo Grant Valeant Pharmaceuticals Exclusive License to Market Opana(r) ER in Canada, Australia and New Zealand
Jun 09, 2009 07:31 AM | ENDP, PPCO, VRX
- Form 4 ENDO PHARMACEUTICALS For: Dec 31 Filed by: Spengler William (10K)
Jan 05, 2010 05:37 PM
- Form 4 ENDO PHARMACEUTICALS For: Dec 31 Filed by: Scodari Joseph C (10K)
Jan 05, 2010 05:37 PM
- Form 4 ENDO PHARMACEUTICALS For: Dec 31 Filed by: MONTAGUE WILLIAM P (10K)
Jan 05, 2010 05:36 PM
- Form 4 Scodari Joseph C For: Sep 30 (10K)
Oct 01, 2009 08:34 PM
- Form 4 MONTAGUE WILLIAM P For: Sep 30 (10K)
Oct 01, 2009 08:33 PM
- Form 4 Spengler William For: Sep 30 (10K)
Oct 01, 2009 08:30 PM
- Form 4 Holveck David For: Sep 01 (10K)
Sep 04, 2009 10:07 AM
- Form 4 LEVIN ALAN G For: Jul 28 (10K)
Jul 29, 2009 07:34 PM
- Form 4 MONTAGUE WILLIAM P For: Jun 30 (10K)
Jul 01, 2009 07:57 PM
- Form 4 Scodari Joseph C For: Jun 30 (10K)
Jul 01, 2009 07:56 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
ENDP
|
Compare to S&P
|
| YTD |
-4.63 %
|
-0.25 %
|
| 4 Weeks |
-4.07 %
|
3.02 %
|
| 12 Weeks |
-13.79 %
|
-11.58 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -13.70 %
|
|
EPS Growth in Last Year: 3.28 %
|
|
Sales Growth in Last Quarter: -3.24 %
|
|
Sales Growth in Last Quarter: 13.97 %
|
|
